Community and rural hospitals serve the populations most underrepresented in clinical trials — and most needed by pharma to meet FDA diversity requirements. That makes your patient database one of the most commercially valuable assets in clinical research today.
82,400
Patients screened
2,847
Active trial matches
$48,200
Revenue this month
58 days
Time to first revenue
$0 cost to join · PHI never leaves your system
The Diversity Gap in Clinical Trials
3%
Black trial participants
Despite double the prostate cancer incidence rate vs white Americans
<5%
Latino participants
Despite representing 18% of the US population
~0%
Rural patients in trial databases
Despite disproportionate cardiology, diabetes, CNS disease burden
The FDA Response
The FDA's 2023 Action Plan for Enhancing the Diversity of Clinical Trial Populations requires pharma sponsors to submit diversity action plans for Phase 3 trials. Pharma now has a regulatory mandate to find the patients your hospital serves — and they are willing to pay to access them.
You sit at the intersection of the populations pharma needs most and the geographic coverage that urban academic centers cannot provide. That is leverage. Hekma helps you use it.
Passive matching running. 80,000 patients screened continuously against active trials. Zero clinical workflow disruption.
First pharma inquiry within 30 days. Per-insight revenue flowing within 60 days of going live.
No physician involvement in the matching process. No coordinator workload increase. Your revenue changes. Your care delivery does not.
Compliance & Standards
Connect your EHR. Start earning from your existing patient population. Zero cost to join.